Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Servier

Main focus: Gene editing for the development of CAR-T cells

Company stage: Clinical

Diseases: Haematological cancers and solid tumours

Genome editing tool: ARCUS genome-editing platform (licensed from Precision Biosciences), TALEN (Cellectis/Allogene Therapeutics)

Funding stage: Private

Location: Suresnes, France

Website: https://servier.com/en/

Pipeline: https://servier.com/en/areas-of-expertise/research-and-development/development-portfolio/

Partners: Allogene Therapeutics, Cellectis

Servier is a privately held, France-based, international big pharma company. The company has been in operation since 1954, and employs around 20,000 employees today. The company has established several contracts with high profile gene therapy companies, including a CAR-T development deal with Precision Biosciences and an allogeneic CAR-T deal with Allogene Therapeutics.

Tags

HashtagADIR-SERVIER

Company: Servier
close
Search CRISPR Medicine